Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · e752-e766
DOI: 10.1016/j.clml.2026.03.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Samer Al Hadidi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: Samer.AlHadidi@UTSouthwestern.e…. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Neoplasm Recurrence, Local. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Global Services LLC.
Abstract (Originalsprache)
Although treatments have greatly improved outcomes in patients with newly diagnosed multiple myeloma (MM), most patients will relapse after initial therapy and require subsequent treatment. With the wide variety of available treatment regimens (including new combinations of approved therapies) and the need to tailor MM treatment based on disease- and patient-centric factors, it can be challenging to select an appropriate treatment at first relapse. This decision should also consider the effect of second-line therapy on future treatment options for eligible patients, particularly chimeric antigen receptor T-cell (CAR-T) therapy and other T-cell-engaging therapies (eg, bispecific antibodies) targeting B-cell maturation antigen or other tumor antigens. Treatment selection should prioritize therapies with the greatest survival benefit to reduce risk of attrition with subsequent lines of therapy. Key considerations include patient age, performance status, comorbidities, cytogenetics, prior drug exposure, and duration of response to initial therapy. Furthermore, early referral before CAR-T therapy is highly recommended to prepare for treatments received before apheresis (ie, holding therapy) as well as treatments received during CAR-T manufacturing, between apheresis and CAR-T infusion (ie, bridging therapy). The timing of referral for CAR-T therapy is critical, as CAR-T manufacturing may require 3-4 weeks or longer depending on product, during which time, disease progression may occur without effective bridging therapy. In this article, we provide insights from experienced physicians on approaches for optimizing second-line therapy in patients with MM who have relapsed after initial treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: Samer.AlHadidi@UTSouthwestern.edu.
- Division of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, CA.
- Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL.
- Division of Hematology, Medical College of Wisconsin, Milwaukee, WI.
- Oncology & Infusion Therapy, York Hospital, York, ME.
- Hematology Oncology Associates of CNY, Syracuse, NY.
Förderung
- Janssen Global Services LLC
Zitieren
APA
Al Hadidi, S., Costello, C., Costa, L. J., Dhakal, B., Georges, P., Gajra, A., Lin, Y., Bhargava, R. S., Paner-Straseviciute, A., & Vij, R. (2026). Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection. Clinical Lymphoma Myeloma and Leukemia, 26(6), e752-e766. https://doi.org/10.1016/j.clml.2026.03.009
Vancouver
Al Hadidi S, Costello C, Costa LJ, Dhakal B, Georges P, Gajra A, et al. Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):e752-e766. doi:10.1016/j.clml.2026.03.009
BibTeX
@article{AlHadidi2026,
author = {Al Hadidi, Samer and Costello, Caitlin and Costa, Luciano J and Dhakal, Binod and Georges, Peter and Gajra, Ajeet and Lin, Yi and Bhargava, Ranjana S and Paner-Straseviciute, Agne and Vij, Ravi},
title = {Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {6},
pages = {e752--e766},
doi = {10.1016/j.clml.2026.03.009}
}
EUVIMED